Skip to content
2000
Volume 21, Issue 2
  • ISSN: 1573-4021
  • E-ISSN: 1875-6506

There is no abstract available.

Loading

Article metrics loading...

/content/journals/chyr/10.2174/0115734021388726250429102020
2025-04-29
2025-09-25
Loading full text...

Full text loading...

/deliver/fulltext/chyr/21/2/CHR-21-2-07.html?itemId=/content/journals/chyr/10.2174/0115734021388726250429102020&mimeType=html&fmt=ahah

References

  1. ManciaG. ReaF. CorraoG. GrassiG. Two-drugs combination as first step antihypertensive treatment.Circ. Res.201912471113112310.1161/CIRCRESAHA.118.313294 30920930
    [Google Scholar]
  2. FaragS.M. RabeaH.M. AbdelrahimM.E.A. MahmoudH.B. Target blood pressure and combination therapy: Focus on angiotensin receptor blockers with either calcium channel blockers or beta-blockers.Curr. Hypertens. Rev.202218213814410.2174/1573402118666220627120254 36508272
    [Google Scholar]
  3. GrassiG. Highlights from the new European Society of Hypertension guidelines document.Curr. Hypertens. Rev.2024202666910.2174/0115734021309169240508110407 38757319
    [Google Scholar]
  4. OzawaY. HayashiK. KoboriH. New generation of calcium channel blockers in hypertensive treatment.Curr. Hypertens. Rev.20062210311110.2174/157340206776877370 19823601
    [Google Scholar]
  5. ZhuJ. ChenN. ZhouM. Calcium channel blockers versus other classes of drugs for hypertension.Cochrane Database Syst. Rev.202211CD00365410.1002/14651858.CD003654.pub6 35000192
    [Google Scholar]
  6. WangH. YangH. ZhangZ. GuoH. Efficacy and safety of dihydropyridine calcium channel blockers for primary hypertension: A Bayesian network meta-analysis.Curr. Hypertens. Rev.202520252110.2174/0115734021357729250214090452 39995131
    [Google Scholar]
  7. OparilS. AcelajadoM.C. BakrisG.L. Hypertension.Nat. Rev. Dis. Primers2018411801410.1038/nrdp.2018.14 29565029
    [Google Scholar]
  8. TakenakaT. OhnoY. SuzukiH. Clinical science of calcium channel blocker to inhibit hypertensive vascular injury.Curr. Hypertens. Rev.20149319320110.2174/1573402110666140131161947 24479753
    [Google Scholar]
  9. GrassiG. Sympathetic modulation as a goal of antihypertensive treatment: From drugs to devices.J. Hypertens.202341111688169510.1097/HJH.0000000000003538 37602470
    [Google Scholar]
  10. GrassiG. SeravalleG. TurriC. BollaG. ManciaG. Short-versus long-term effects of different dihydropyridines on sympathetic and baroreflex function in hypertension.Hypertension200341355856210.1161/01.HYP.0000058003.27729.5A 12623959
    [Google Scholar]
/content/journals/chyr/10.2174/0115734021388726250429102020
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test